Hyperhidrosis

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 28, 2024
AstraZeneca, Exercise, Fortification, New Drug Application, Patient, GBM, CRL, NDA, Menkes, Minocycline, Therapy, Marketing, Radiation, CKPT, Rosacea, Investigational New Drug, Erythema, Safety, BLA, Fortress Biotech, Food, Red, Amyloidosis, Dermatology, Carcinoma, FDA, Hyperhidrosis, Mustang Bio, Menkes disease, PDUFA, Pharmaceutical industry

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In 2023, we built a significant amount of momentum to position our Company to achieve multiple milestones in 2024.
  • In March 2024, the FDA accepted the NDA and has set a PDUFA goal date of November 4, 2024.
  • In December 2023, the FDA issued a complete response letter (“CRL”) for the cosibelimab BLA.
  • Fortress’ consolidated net revenue totaled $84.5 million for the full year ended December 31, 2023, which included $59.7 million in net revenue generated from our marketed dermatology products.

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024
Research, U.S. FDA, Conference, Growth, Journey, Agreement, FY, IGA, Microbiota, Risk, New Drug Application, Patient, Food and Drug Administration, Rosacea, Hyperhidrosis, NDA, Red, News, Adjustment, Dermatology, Clinical trial, Erythema, Doxycycline, Safety, GAAP, Food, Marketing, FDA, CEA, Total, PDUFA, Pharmaceutical industry

SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.

Key Points: 
  • ET to discuss the financial results and provide a business update
    SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.
  • Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2023 was a year of growth and development for Journey Medical.
  • In December 2023, Journey Medical entered into a $20.0 million credit facility with SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector.
  • In July 2023, Journey Medical announced positive topline results from the two DFD-29 Phase 3 clinical trials (MVOR-1 & MVOR-2) for the treatment of rosacea.

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, February 28, 2024
Research, Clinical Trials, Biotechnology, Managed Care, Health, Cosmetics, Pharmaceutical, Retail, Science, Acne, Nemolizumab, Pacific Ocean, Atopic dermatitis, Prurigo nodularis, Hyperhidrosis, Dermatology, Skin, Consultant, AAD, Marriott Marquis, Safety, Patient, Itch, START, American Academy, Medical device

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

Key Points: 
  • Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
  • “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action.
  • The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.
  • *All presenters are paid consultants or employees of Galderma.

miraDry® Appoints Medical Aesthetic Leaders Amber Edwards as Chair and Robert Catlin as New Chief Executive Officer

Retrieved on: 
Tuesday, January 16, 2024
Dermatology, Patient, Hyperhidrosis, Merz, Culture, SVP, Amber, Chair, Allergan, Perspiration, FDA, Capital, Bausch Health, Endo International, Growth, Management

NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer. Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company. Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer.
  • Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company.
  • Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.
  • "We are thrilled to have Rob Catlin join this dynamic team bringing broad commercial leadership experience in dermatologic and aesthetic categories.

miraDry® Appoints Medical Aesthetic Leaders Amber Edwards as Chair and Robert Catlin as New Chief Executive Officer

Retrieved on: 
Tuesday, January 16, 2024
Dermatology, Patient, Hyperhidrosis, Merz, Culture, SVP, Amber, Chair, Allergan, Perspiration, FDA, Capital, Bausch Health, Endo International, Growth, Management

NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer. Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company. Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer.
  • Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company.
  • Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.
  • "We are thrilled to have Rob Catlin join this dynamic team bringing broad commercial leadership experience in dermatologic and aesthetic categories.

AMERICAN ACADEMY OF DERMATOLOGY: START THE NEW YEAR OFF WITH A FRESH START (AND SKIN)

Retrieved on: 
Tuesday, January 9, 2024
Laser, Patient, FAAD, Dermatology, Social media, MD, Health, Face, Knowledge, Perspiration, AAD, Eyebrow, New Year's, Skin, Hyperhidrosis, Common, Ageing, Education, Physician, Cosmetics

ROSEMONT, Ill., Jan. 9, 2024 /PRNewswire/ -- With a rise in both public accessibility and visibility, cosmetic treatments are more popular than ever. Whether your New Year's resolution is to improve your health or to look and feel your best, the most important thing to remember is that your results depend largely on the skills and knowledge of the person performing your treatment.

Key Points: 
  • "There is no one-size-fits-all or 'cookie cutter' approach to combat the signs of aging because aging looks different on everyone.
  • On the flipside, there is no one cosmetic treatment to address all of these changes," said Lauren Fine, MD, FAAD, a board-certified dermatologist in Chicago.
  • While over-the-counter options are available, they may not be able to provide the results that a cosmetic procedure can deliver.
  • If you have specific cosmetic concerns or questions about a particular treatment, the best place to start is with a board-certified dermatologist.

PatientFi Appoints Ray Bassi as New Senior Vice President, Sales

Retrieved on: 
Monday, January 8, 2024
Practice Management, Payments, Finance, Health, Health Technology, Professional Services, Technology, Fintech, Entrepreneurship, Dermatology, AB toxin, Allergan, Growth, Patient, Deoxycholic acid, Hyperhidrosis, AbbVie, Senior, Pharmaceutical industry

PatientFi , the company which offers healthcare practices payment plans and membership solutions to increase affordability for elective procedures, today announced that aesthetic industry veteran Ray Bassi has joined the company as Senior Vice President, Sales.

Key Points: 
  • PatientFi , the company which offers healthcare practices payment plans and membership solutions to increase affordability for elective procedures, today announced that aesthetic industry veteran Ray Bassi has joined the company as Senior Vice President, Sales.
  • Prior to leaving Allergan Aesthetics, Ray served as Vice President of Sales, overseeing the U.S. injectable portfolio sales team, comprised of 300+ employees.
  • Ray joined Dermira, after leaving Allergan, as Vice President of Sales where he helped launch QBREXZA, a topical treatment for axillary hyperhidrosis.
  • Prior to joining PatientFi, Ray served as Vice President of Sales for DermTech, a skin genomics company, where he led the expansion of the sales organization.

Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Plasma protein binding, Constipation, INN, Risk, Hypotension, Hypertension, Fatigue, Nausea, Cancer, Inflammation, Tachypnea, Back pain, Chest pain, Diagnosis, Anatomy, Cough, IIA, CHMP, Chills, Diarrhea, Fever, ATC, Pain, European, Disease, Ageing, Weakness, Nonsteroidal anti-inflammatory drug, Human, Tachycardia, Anemia, Arthralgia, Medical Subject Headings, European Commission, Immune system, International, Language, Somatic symptom disorder, Myalgia, Dizziness, Monocyte, Select, Patient, Medicine, Hyperhidrosis, Vomiting, Allergy, Headache, Mifamurtide, Macrophage, Abdominal pain, Hypothermia, Chronic pain, Safety, Committee, Periodic breathing, Medical device

Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised

VERB's MARKET.live Expands Vendor Acquisition With 15 More Retailers Joining Its Live Social Shopping Platform

Retrieved on: 
Monday, November 20, 2023
Dermatology, Tea, LAS, LOS, Beauty, Social media, Art, Paris Fashion Week, Trendsetter, Hyperhidrosis, Outside (magazine), House, Online shopping

Retailers and creators that join MARKET.live have the ability to broadcast livestream shopping events simultaneously on numerous social media channels, as well as on MARKET.live, reaching exponentially larger audiences.

Key Points: 
  • Retailers and creators that join MARKET.live have the ability to broadcast livestream shopping events simultaneously on numerous social media channels, as well as on MARKET.live, reaching exponentially larger audiences.
  • - LondonTown: A trendsetter in the beauty industry, LondonTown has garnered recognition for its nail care innovations, earning the Allure Best of Beauty Award.
  • - Duradry: Recognized for its effectiveness in addressing hyperhidrosis, Duradry has been praised by dermatologists and users alike, earning high ratings and testimonials.
  • For more information, please visit MARKET.live or follow the latest updates on social media.

Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, November 14, 2023
NDA, Fortress Biotech, Food, SBMA, BLA, Exercise, Patient, Agreement, FDA, Marketing, New Drug Application, Fortification, Rosacea, Hyperhidrosis, PDUFA, Dermatology, Video game, Pharmaceutical industry, NFE2L2, Avenue, Hong Kong, Checkpoint

MIAMI, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In the third quarter of 2023, Fortress and our partner companies and subsidiaries continued to advance our diverse portfolio of drug candidates.
  • Journey Medical’s total product net revenues were $15.3 million for the third quarter of 2023, compared to third quarter 2022 total product net revenues of $16.0 million.
  • Fortress’ consolidated net revenue totaled $34.8 million for the third quarter of 2023, which included $15.3 million in net product revenue generated from our marketed dermatology products.
  • Consolidated selling, general and administrative expenses were $21.7 million for the third quarter of 2023, compared to $30.1 million for the third quarter of 2022.